Attendees will have the opportunity to see DISQOVER in action and learn more about how it can help them unlock hidden insights from their data to improve patient outcomes. DISQOVER's semantic technology and ontology-based knowledge graph enables more efficient data exploration and analysis, making it a trusted platform among leading pharmaceutical and biotech companies.

Unlocking novel therapeutic targets: a synergy of cutting-edge science and data harmonization | 4 October @ 12:45 

Presented by James Longden, Head of Discovery Biology at e-therapeutics & Carl Latham, VP of Sales and Partnerships at ONTOFORCE.

Learn about HepNet, a human-machine interface for RNAi target discovery and ONTOFORCE's DISQOVER platform.

The major challenge for mature treatment modalities like RNAi is the identification of novel targets. Typically, target identification approaches involve the search for individual proteins in well-characterized pathways. However, such reductionist approaches are prone to failure because they do not reflect the intricate complexity of human biology. Proteins are highly interlinked in inter- and intracellular signaling networks, and diseases often stem from abnormalities within these networks, rather than isolated gene aberrations. 

e-therapeutics aims to understand disease using their suite of proprietary computational models to build and interrogate protein-protein interactions. To support this work they are developing a centralized interface, HepNet, that will give biologists access to large-scale data currently only amenable to computational interrogation and also the ability to participate in the selection of targets in concert with artificial intelligence algorithms.